Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $317.00 USD
Change Today +3.66 / 1.17%
Volume 2.3M
BIIB On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

biogen inc (BIIB) Snapshot

Open
$312.54
Previous Close
$313.34
Day High
$319.42
Day Low
$310.52
52 Week High
03/20/15 - $480.18
52 Week Low
10/22/14 - $290.85
Market Cap
74.5B
Average Volume 10 Days
4.8M
EPS TTM
$14.67
Shares Outstanding
235.2M
EX-Date
--
P/E TM
21.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOGEN INC (BIIB)

biogen inc (BIIB) Details

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company’s products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS – SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer’s disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS – DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company was formerly known as Biogen Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.

7,550 Employees
Last Reported Date: 02/4/15
Founded in 1985

biogen inc (BIIB) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $698.4K
Chief Strategy Officer and Senior Vice Presid...
Total Annual Compensation: $2.3M
Executive Vice President of Research & Develo...
Total Annual Compensation: $766.8K
Executive Vice President of Global Commercial...
Total Annual Compensation: $675.1K
Compensation as of Fiscal Year 2014.

biogen inc (BIIB) Key Developments

Biogen Enters Collaboration with the Parkinson's Institute and Clinical Center

Biogen and the Parkinson’s Institute and Clinical Center announced the formation of a strategic alliance focused on enhancing the understanding of the underlying biology of Parkinson’s disease (PD) and the creation of novel tools and programs that could accelerate research and the development of new PD treatments. The agreement will combine the unique clinical expertise and data of the Institute with Biogen’s focus on neurodegenerative disease and approach to clinical development. The multi-year collaboration includes an array of PD-related activities designed to drive advances in basic science and treatment including:Discovery of gene targets and modifier genes that might serve as novel therapeutic targets. The creation of well-defined patient-derived induced pluripotent stem cells (iPSC). The collaborative effort will be enhanced by rich information from the Institute’s Brain and Tissue Knowledge Bank, which contains patient biological samples, profiles, family health histories, and clinical outcomes.

Biogen Inc. Reports Un-Audited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year 2015

Biogen Inc. reported un-audited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues of $2.6 billion, a 7% increase compared to $2.4 billion in the second quarter of 2014. Non-GAAP diluted earnings per share (EPS) were $4.22, an increase of 21% over the $3.49 reported in second quarter of 2014. Non-GAAP net income attributable to the company was $994.8 million, an increase of 20% over the $829.1 million reported in second quarter of 2014. On a reported basis, GAAP diluted EPS were $3.93, an increase of 31% over $3.01 reported in the second quarter of 2014. GAAP net income attributable to the company was $927.3 million, an increase of 30% versus $714.5 million in the same period in the prior year. The company reported income from operations of $1,233.1 million compared to $988.7 million, income before income tax expense and equity in loss of investee, net of $1,222.2 million compared to $993.6 million for the last year. For the six months, the company reported revenues of $5.1 billion compared to $4.6 billion, non-GAAP diluted earnings per share (EPS) of $8.04 compared to $5.96, non-GAAP net income attributable to the company of $1,895.0 million compared to $1,415.9 million, on a reported basis, GAAP diluted EPS of $7.42 compared to $5.03, GAAP net income attributable to the company of $1,749.8 million versus $1,194.5 million, income from operations of $2,351.0 million compared to $1,660.1 million and income before income tax expense and equity in loss of investee, net of $2,325.1 million compared to $1,659.3 million for the last year. For the year 2015, the company expected revenue growth to be approximately 6% to 8% compared to 2014, a decrease from prior guidance based largely on revised expectations for the growth of TECFIDERA. GAAP diluted EPS is expected to be between $14.25 and $14.70, a decrease from prior guidance. Non-GAAP diluted EPS is expected to be between $15.50 and $15.95, a decrease from prior guidance. Projected GAAP net income attributable to the company is $3,411.6 million and non-GAAP net income attributable to the company of $3,705.7 million. The company anticipates capital expenditures of approximately $650 million to $700 million, an increase over 2014, as continue to expand manufacturing footprints.

Biogen Announces New Results from a Prespecified Interim Analysis of Prime, the Phase 1b Placebo-Controlled Study of Aducanumab (BIIB037) in Patients with Prodromal or Mild Alzheimer’s Disease

Biogen announced new results from a prespecified interim analysis of PRIME, the Phase 1b placebo-controlled study of aducanumab (BIIB037) in patients with prodromal or mild Alzheimer’s disease (AD). In this analysis, which includes patients treated up to 54 weeks with the 6 mg/kg dose, aducanumab demonstrated acceptable safety and tolerability, and the findings reinforce the previously reported results from PRIME. These data are being presented at the Alzheimer’s Association International Conference® 2015 (AAIC®) in Washington, D.C. Consistent with previously reported results, the 54-week data from the 6 mg/kg arm demonstrated a statistically significant reduction of beta amyloid in the brain. In exploratory analyses, the 6 mg/kg dose showed an improvement in the slowing of clinical decline, as measured by the Mini Mental State Examination (MMSE) and Clinical Dementia Rating sum of boxes (CDR-SB) scales, which was not statistically significant. In a pre-specified analysis across placebo and all doses of aducanumab, the slowing of clinical decline was shown to be dose-dependent, and this dose-dependence achieved statistical significance for both scales. Clinical Results: The updated results of the MMSE showed that patients in the placebo group worsened by an average of 2.81 points at 52 weeks. Clinical decline on the MMSE in the treatment arms was 2.18 points in the 1 mg/kg, 0.70 in the 3 mg/kg, 1.96 in the 6 mg/kg and 0.56 in the 10 mg/kg. Relative to placebo, the 3 and 10 mg/kg doses demonstrated a statistically significant slowing of cognitive decline on the MMSE, both with p-values <0.05. The 1 and 6 mg/kg were not statistically significant. The linear trend for dose response was statistically significant with a p-value less than 0.05. The updated results of the CDR-SB showed that patients in the placebo group worsened by an average of 1.87 points at 54 weeks compared to 1.72 in the 1 mg/kg, 1.37 in the 3 mg/kg, 1.11 in the 6 mg/kg and 0.63 in the 10 mg/kg treatment arm. The 10 mg/kg arm demonstrated a statistically significant slowing of clinical decline compared to placebo on the CDR-SB with p-value <0.05. The 1, 3 and 6 mg/kg were not statistically significant. The linear trend for dose response was statistically significant with a p-value less than 0.05. Pharmacokinetic activity and exposure were linear with dose. Treatment-emergent immunogenicity, which occurred in three% of aducanumab treated patients, was transient and without an apparent effect on aducanumab PK. Safety Results: Aducanumab demonstrated an acceptable safety and tolerability profile in this analysis that was consistent with previously reported analyses from this study. The most frequently reported treatment-related serious adverse event (SAE) and adverse event (AE) was ARIA (amyloid-related imaging abnormalities). Based on MRI scans, the incidence of ARIA-E (edema) was dose- and apolipoprotein E4- (ApoE4) status-dependent. In general, the onset of ARIA-E was observed early in the course of treatment and was asymptomatic or with mild, transient symptoms. The majority of patients with ARIA-E continued treatment at a lower dose. In ApoE4 carriers, the incidence of ARIA-E was 5% in the 1 mg/kg and 3 mg/kg arms, 43% in the 6 mg/kg arm and 55% in the 10 mg/kg arm. In ApoE4 non-carriers, the incidence of ARIA-E was 9% in the 3 mg/kg, 22% in the 6 mg/kg and 17% in the 10 mg/kg aducanumab arm; no cases were reported in the 1 mg/kg arm. In ApoE4 carriers, the incidence of patients who developed ARIA-E and discontinued treatment was 5% in the 1 mg/kg arm, 10% in the 6 mg/kg arm and 35% in the 10 mg/kg arm. There were no discontinuations in the 3 mg/kg arm. In ApoE4 non-carriers, the incidence of patients who developed ARIA-E and discontinued treatment was 11% in the 6 mg/kg arm and 8% in the 10 mg/kg arm. There were no discontinuations in the 1 mg/kg and 3 mg/kg arms. Overall, 56% of subjects who developed ARIA-E continued treatment at the same or lower dose and none developed recurrent ARIA-E. Headache occurred in 20% of patients receiving aducanumab compared to 5% in the placebo groups and appeared to be dose-dependent. Three deaths were reported in the time period of this analysis, two in the placebo group and one in the 10 mg/kg study arm; none were considered to be treatment related. Other AEs and SAEs were consistent with what is typically observed in the study population.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIIB:US $317.00 USD +3.66

BIIB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.77 USD -0.29
Astellas Pharma Inc ¥1,867 JPY +15.00
Celgene Corp $131.88 USD -0.26
Shire PLC 5,625 GBp +35.00
Thermo Fisher Scientific Inc $139.12 USD -0.50
View Industry Companies
 

Industry Analysis

BIIB

Industry Average

Valuation BIIB Industry Range
Price/Earnings 21.2x
Price/Sales 7.2x
Price/Book 5.9x
Price/Cash Flow 18.9x
TEV/Sales 6.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN INC, please visit www.biogenidec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.